Table of Contents
Journal of Allergy
Volume 2011 (2011), Article ID 479129, 4 pages
http://dx.doi.org/10.1155/2011/479129
Case Report

A Case of Severe Bronchial Asthma Controlled with Tacrolimus

1The Department of Internal Medicine, Toyama Prefectural Central Hospital, 2-2-78 Nishinage, Toyama 930-8550, Japan
2The Department of Radioloy, Toyama Prefectural Central Hospital, 2-2-78 Nishinage, Toyama 930-8550, Japan

Received 6 December 2010; Accepted 7 February 2011

Academic Editor: Redwan Moqbel

Copyright © 2011 Hirokazu Taniguchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Wenzel, J. V. Fahy, C. Irvin et al., “Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 6, pp. 2341–2351, 2000. View at Google Scholar · View at Scopus
  2. T. Fukuda, “Immunosuppressive agents and asthma,” Clinical Reviews in Allergy, vol. 12, no. 1, pp. 95–108, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. J. Corrigan, P. H. Brown, N. C. Barnes, J. J. Tsai, A. J. Frew, and A. B. Kay, “Glucocorticoid resistance in chronic asthma: peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A,” American Review of Respiratory Disease, vol. 144, no. 5, pp. 1026–1032, 1991. View at Google Scholar · View at Scopus
  4. B. Abraham, J. M. Antó, E. Barreiro et al., “The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma,” European Respiratory Journal, vol. 22, no. 3, pp. 470–477, 2003. View at Publisher · View at Google Scholar
  5. S. E. Wenzel, L. B. Schwartz, E. L. Langmack et al., “Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 3, pp. 1001–1008, 1999. View at Google Scholar · View at Scopus
  6. A. Szczeklik, E. Nizankowska, R. Dworski, B. Domagala, and G. Pinis, “Cyclosporin for steroid-dependent asthma,” Allergy, vol. 46, no. 4, pp. 312–315, 1991. View at Google Scholar · View at Scopus
  7. A. G. Alexander, N. C. Barnes, and A. B. Kay, “Trial of cyclosporin in corticosteroid-dependent chronic severe asthma,” Lancet, vol. 339, no. 8789, pp. 324–328, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. G. A. Dos Reis and E. M. Shevach, “Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell,” Journal of Immunology, vol. 129, no. 6, pp. 2360–2367, 1982. View at Google Scholar · View at Scopus
  9. B. Ryffel, “Pharmacology of cyclosporine. VI. Cellular activation: regulation of intracellular events by cyclosporine,” Pharmacological Reviews, vol. 41, no. 3, pp. 407–422, 1989. View at Google Scholar · View at Scopus
  10. T. Sano, Y. Nakamura, Y. Matsunaga et al., “FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma,” European Respiratory Journal, vol. 8, no. 9, pp. 1473–1478, 1995. View at Google Scholar · View at Scopus
  11. A. P. Sampson, “The role of eosinophils and neutrophils in inflammation,” Clinical and Experimental Allergy, Supplement, vol. 30, no. 1, pp. 22–27, 2000. View at Google Scholar · View at Scopus
  12. G. Cox, “Glucocorticoid treatment inhibits apoptosis in human neutrophils: separation of survival and activation outcomes,” Journal of Immunology, vol. 154, no. 9, pp. 4719–4725, 1995. View at Google Scholar · View at Scopus